清心饮Ⅱ号对病毒性心肌炎小鼠药效学的研究

Pharmacodynamic study of Qingxinyin II on viral myocarditis in mice model

目的 通过前期拆方研究后而组成的清心饮Ⅱ号进行不同剂量的药效学与作用机制研究 ,明确该方在实验动物中的有效治疗剂量 ,为新药开发提供实验依据。方法 通过检测用药 10d后小鼠体重变化、血清中肌钙蛋白Ⅰ (cTnI)、SOD及MDA的变化、小鼠心肌中病毒滴度水平 ,验证该方的疗效。结果 清心饮Ⅱ号高剂量组和中剂量组均能有效降低小鼠心肌中病毒滴度和减轻心肌中的病理改变 ;清心饮Ⅱ号中剂量组能显著降低小鼠血清中cTnI的含量 ,清心饮Ⅱ号高、中剂量组均能有效提高血清中SOD含量和降低血清中MDA的水平。

OBJECTIVE By pharmacodynamics study on different dose of Qingxinyin II(QXY II), which was developed based on the previous variation study of recipe components, the effective dose of QXY II for experimental animal was verified to support the future new medicine development. METHOD Treatment effectiveness of QXY II was demonstrated by measuring the virus titers level in mice myocarditis and changes in mice body weight, the serum cardiac troponin I (cTnI), superoxide Dismutase (SOD) and malon dialdehyde (MDA) after 10 days treatment. RESULTS High dose and middle dose group both can effectively decrease the virus titers and the pathological changes in mice myocarditis, raise the SOD level in serum while lower the level of MDA. Middle dose group can significantly lower the level of cTnI in serum. CONCLUSION Significant treatment effectiveness of QXY II was found, especially for high dose and middle dose group.